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Early detection of cancer along with modern medicine has led 
to a rise in the survival rates of young cancer patients.  This 
results in many cancer survivors who are capable of childbear-
ing. However, since chemotherapy and radiation given during 
the cancer curing process can result in various fertility issues, 
patients must find a method to preserve their ability to give 
birth to children.  
One method of preservation is oocyte cryopreservation. 
Human oocyte cryopreservation is a procedure in which a 
woman’s oocytes are extracted, frozen and then stored. When 
the woman desires to become pregnant the eggs are thawed, 
fertilized and transferred in to the uterus.   
This type of preservation is preferred by many for various rea-
sons.  Many single cancer patients prefer freezing unfertilized 
eggs, as opposed to fertilized ones, as they don’t need any male 
donors at the time.  Another reason women may want to freeze 
eggs is due to the fact that oocyte quality and quantity diminish-
es with age.   This can cause a lack of healthy eggs to allow for 
pregnancy.  Considering this, many women may prefer to freeze 
their healthy young and vital oocytes, which are more likely to 
produce pregnancies.  
Furthermore, people may consider oocyte cryopreservation 
due to ethical, legal and religious hindrances that prevent them 
from doing embryo cryopreservation. Couples may not want to 
cryopreserve embryos as the embryos may have to be disposed 
if the cancer patient dies. (Noyes, et. al. 2010) 
The goal of this study is to determine if oocyte cryopreserva-
tion is a means that enables women to have healthy offspring, 
post anti-mitotic therapy.
Methods
Pub med.gov, google scholar and Touro databases such as, 
EBSCO host, were used to research relevant studies and re-
views for the background, process and results of oocyte cryo-
preservation. The review paper’s references were used to find 
additional original papers that were relevant to the question 
proposed above. Key words such as oocyte cryopreservation, 
oocyte cryopreservation in cancer patients, slow freezing and 
vitrification were used in order to find articles.
Discussion
Various studies were done on oocyte cryopreservation. In one 
experiment, twenty-two cancer patients, between ages 21 and 
38, underwent cycles of oocyte cryopreservation. After drug 
stimulation, oocytes were harvested from sixteen of the twen-
ty-two infertile women, subsequently fertilized and implanted in 
them. The other six infertile patients received donor eggs. Only 
mature oocytes were preserved. The eggs were preserved by 
two methods, slow cooling method and vitrification. A total of 
295/355 oocytes were recovered with a 92% survival rate.  
At the time of publication of the study, fourteen of the patients 
had become pregnant, one had miscarried, and three pregnan-
cies were still ongoing.  A total of thirteen babies were born to 
the other expectant ten patients. Eleven of these babies were 
completely healthy, however a set of twins were born prema-
turely due to premature dilatation of an incompetent cervix. 
These twins suffered some complications of prematurity, but 
upon reaching two years of age, the twins were thriving within 
the average norms.  Besides for two cases of gestational diabe-
tes, no other complications were reported (Grifo, Noyes, 2010). 
Gestational diabetes is common in women during pregnancy. 
According to the CDC, the ratio of women with gestational 
diabetes ranges between one in every twenty to one in every 
fifty of expectant women.
Additionally, Dr. Nicole Noyas and other researchers pooled 
together data to see how many oocyte cryopreservation’s re-
sulted in normal babies. Any incomplete data was left out. A 
total of six hundred and nine births were reported between 
the years 1986-2008. All the babies born were a result of oo-
cyte cryopreservation. However, the oocytes in those six hun-
dred and nine births were preserved using different methods 
of cryopreservation. Three hundred and eight went through 
the process of slow freezing, two hundred eighty nine were 
preserved using vitrification and twelve had a combination of 
slow freezing and vitrification. A total of eight anomalies were 
reported.  There were also three hundred twenty seven cryo-
preserved oocyte births published, totaling nine hundred thirty 
Abstract
Anti-mitotic therapies are a form of therapy used to treat cancer patients.  The use of these treatments on females 
can result in fertility complications. Therefore, prior to treatment, women must seek ways to preserve their ability to 
conceive children after receiving treatment. This study analyzes the outcomes of oocyte cryopreservation and its many 
variables. Three important variables that can affect the outcome of oocyte cryopreservation are age, cryopreservation 
method and cryoprotectants.  Evidence indicates that human oocyte cryopreservation can enable a woman to preserve 
her ability to give birth to a healthy child, following anti-mitotic therapies. Hundreds of babies have been born as a result 




Esther Gellis is graduating in January 2017 with a BS in Biology.
156
Esther Gellis
six births. Out of the nine hundred thirty six babies, twelve ba-
bies were born with birth defects. Overall the anomaly rate is 
1.3%. According to the CDC, three percent of babies are born 
with major structural or genetic defects. The twelve defects and 
the total incidents statistically occurring in natural conception 
babies compared to oocyte cryopreservation babies are listed 
in table 1. (Noyes, et. al. 2009) 
From the table one can assess that there were no neural tube 
defects and that the defect of skin hemangioma is the same 
range as babies born from natural conception. Additionally, cleft 
lip and palate as well as cardiac defects occurred less in the 
babies born as a result of oocyte cryopreservation. 
Researchers have tried to improve the process of oocyte 
cryopreservation. One issue that arose from freezing the eggs 
was that extensive intracellular ice formed during freezing. 
Extensive intracellular ice can cause cellular disruption in the 
oocyte during the oocyte cryopreservation process. This can 
possibly be improved by using cryoprotectants such as, pro-
panediol and sucrose to increase the extent of the dehydration 
process. The aim of the study done by researchers in Infertility 
and IVF Center of Buda was to introduce their preliminary clin-
ical results with oocyte cryopreservation. They used slow cool-
ing as the procedure to freeze the eggs. They specifically used 
propanediol (1.5M) and sucrose (0.3 M) as the cryoprotectants. 
After incubating the oocytes for 4-6 hours, the oocytes were 
thawed, fertilized and embryos were transferred into twen-
ty-nine patients. Out of one hundred ten cryopreserved eggs, 
eighty-four survived. This is a 76% survival rate, which is high 
but not optimal. From fifty-two embryo transfers, seven result-
ed in clinical pregnancies, which is 7.3% implantation rate per 
egg thawed. Chorion biopsies that were performed indicated 
that there were no chromosomal abnormalities. Out of the 
seven pregnancies, five of them resulted in four singletons and 
one set of twins. One was still ongoing at the time of the study 
and the seventh spontaneously aborted in the tenth week. No 
abnormalities were indicated in the study. Additionally, there 
was only a small difference in the pregnancy rate, 33% versus 
24%, between those pregnancies that resulted from frozen oo-
cytes and those that resulted from fresh oocytes. As indicated 
from published literature at that time of the research, fifteen to 
thirty oocytes were needed in order to achieve one pregnancy. 
Previously, one hundred to one hundred fifty were needed to 
achieve one pregnancy. (Konc, et. al. 2008) The results show 
that oocyte cryopreservation is improving over time.
Vitrification is also known as ultra-rapid cooling. In recent years, 
vitrification has proven the superior method. Compared to 
slow freezing, vitrification results in higher oocyte survival and 
fertilization. (Cil, et. al. 2013) In a study done to compare the 
outcome of the two methods, the survival, fertilization, preg-
nancy and implantation rates were 57.9% versus 78.9%, 64.6% 
versus 72.8%, 7.6% versus 18.2% and 4.3% versus 9.3% corre-
spondingly. The rates were higher in all steps for the vitrification 
method. (Fadini, et al., 2009) 
The duration of cryostorage doesn’t undesirably affect the 
thawing of frozen oocytes. A study was done to see if there is 
any influence on the outcome of thawing cryopreserved oo-
cytes. There were three groups in the experiment.  Group A’s 
eggs were cryostored for one to three months, group B’s eggs 
were cryostored for four to six months and group C’s were 
cryostored for seven to forty eight months. Group C was fur-
ther divided into three subgroups. Group C1, was cryostored 
for seven to nine months, group C2 was cryostored for ten 
to twelve months and group C3 was cryostored for a total of 
thirteen to forty eight months. The researchers found no signif-
icant difference, from groups A, B and C, in the main outcome 
measurements, which were oocyte survival after thawing, fertil-
ization, implantation, embryo development and quality and birth. 
Oocytes can be cryopreserved for numerous years without 
having an effect on the oocytes quality and performance after 
thawing. (Parmegiani, et. al. 2009)
One factor that may affect the outcome of oocyte cryopreser-
vation is the age. The value of freezing an older woman’s oocytes 
is controversial. (Zhang, et. al. 2015) The rate of implantation of 
the fertilized egg that resulted from the slow freezing and vitri-
fication methods declines with age. A study was done to collect 






Incidence in total 
of 936 oocyte 
cryopreservation 
births (n)
All One in 33 12 (one in 78)
Skin hemangioma One in 50–225 1
Cardiac defects One in 125 3
Neural tube defects One in 385 0
Cleft lip and palate One in 710 1
Clubfoot One in 735 3
Arnold-Chiari syndrome One in 1200 1
Choanal atresia One in 7000 1









Birth anomalies in natural conception versus oocyte cryopreservation, 
listed most common to most rare 




researchers found that live births occur from the slow freez-
ing method until age forty-two, and until age forty-four from 
the vitrification method. They limited their results to the age 
range of twenty five to forty two years old, as there were only 
few cycles that were above or below the twenty-five through 
forty-two year old range. This study’s data was on patients that 
were infertile.  The study was not specifically performed on post 
cancer patients. (Cil, et. al. 2013) 
Furthermore, a study was implemented in order to report the 
oocyte cryopreservation experience in women aged forty and 
older. One hundred fifty eight women, aged forty to forty-nine, 
underwent minimal ovarian stimulation to retrieve their eggs. A 
total of five hundred thirty two eggs were retrieved and frozen. 
Four of the women did not have any oocytes retrieved. A total 
of four hundred eighty five embryos were formed. Out of the 
four hundred eighty five embryos, only fifty-seven were relatively 
healthy. Six clinical pregnancies were achieved. Only three resulted 
in live births. There was a 5.3 % live birth rate per embryo trans-
fer. The other three pregnancies were spontaneously aborted. As 
per the data, a woman aged forty and older can give birth to a 
baby after undergoing the process of freezing her eggs. However, 
there is a low chance that it will indeed happen, as there is a 5.3% 
chance that the woman will give birth. (Zhang, et. al. 2015)
A woman who has ovarian cancer may risk surgical menopause. 
Oocyte cryopreservation can be an option for woman facing 
ovarian cancer. It could also help patients that need to have a 
one or both ovaries removed. A twenty six year old woman 
with borderline ovarian tumors had her oocytes cryopreserved 
after a right adnexectomy. Seven mature eggs were retrieved 
and frozen. Thirty-nine months later, the woman underwent 
a left ovariectomy.  Three embryos were transferred into the 
woman’s uterus. Endometrial growth was achieved with the 
help of hormonal replacement treatment. The woman gave birth 
to healthy twin babies. (Porcu, et al., 2008) 
Oocyte cryopreservation can help women have healthy babies 
even when they don’t have their own healthy eggs. Remaining 
eggs from oocyte cryopreservation cycles can be saved and 
donated to another couple that are experiencing fertility com-
plications. A study was done in which twenty-eight infertile 
women froze their oocytes. Twelve of the twenty-eight women 
had their frozen oocytes thawed. Three of the women used their 
own eggs in IVF treatment and the other twelve donated their 
eggs to other women. Premature ovarian failure, physiological 
menopause, abnormal karyotype and poor ovarian reserve are 
the reasons that the twelve women needed to receive oocytes 
from other women. Seven women became pregnant. Six of the 
seven used donated oocytes. A total of 6 healthy babies were 
born including a set of twins. The other 2 pregnancies were 
aborted due to a blighted ovum. (Li, et al., 2005)
Oocyte cryopreservation may not be for everyone. Women 
with cancers that need to be treated immediately after diagno-
sis, may not be a candidate for oocyte cryopreservation. This is 
because oocyte cryopreservation requires ovarian stimulation 
and retrieval. This can take an average of twelve days. (Noyes, 
et al., 2011) Additionally, some women that have breast cancer 
might run into issues with preserving their eggs. This is because 
estrogen levels rise during ovarian stimulation. High levels of 
estrogen might not be safe for women with breast cancer. 
(Rodriguez-Wallberg, Oktay, 2010)
Furthermore, some women may not want to undergo oocyte 
cryopreservation as it can cause a woman to have a risk hav-
ing of intra-abdominal bleeding and ovarian hyper stimulation 
syndrome. However, there is a very low percentage rate of this 
risk. (Noyes, et al., 2011) Additionally, women with cancers may 
not be able to cryopreserve their eggs due to economic issues. 
It is a very expensive procedure. According to NYU Langone 
Medical Center’s website, oocyte cryopreservation can cost 
about $16,000- $20,000. This includes initial office consulta-
tion, egg cryopreservation cycle, prerequisite blood testing and 
screening medication.  As of 2010, cancer patients are generally 
not offered insurance coverage for oocyte cryopreservation. 
(Noyes, et al., 2011) Consequently, cryopreservation may not 
be an option for people that are struggling financially. 
Conclusion
Oocyte cryopreservation is a viable method that enables 
women post mitotic therapies to have healthy offspring.  As per 
the research discussed above, many women were able to have 
a healthy baby because they froze their oocytes. Even when 
abnormalities were reported, they were basically within nor-
mal range. Oocyte cryopreservation has even enabled a woman 
with borderline ovarian cancer to have a healthy offspring. 
Even though the value of freezing an older woman’s oocytes is 
controversial and the rate of implantation of the fertilized egg 
declines with age, data has shown that oocyte cryopreservation 
can enable older women to have healthy babies.
There are different variables that may increase the outcome of 
oocyte cryopreservation. The vitrification method has shown 
to be the efficient and more reliable method. Cryoprotectants 
such as, propanediol and sucrose can increase the extent of 
the dehydration process and thereby prevent the oocytes from 
disrupting. Furthermore, the duration of cryostorage doesn’t 
undesirably affect the outcome of oocyte cryopreservation.
Oocyte cryopreservation may not be for everyone due to eco-
nomic reasons and timing of the anti-mitotic therapies. However, 
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it is a means that enable women to have healthy children even 
after their oocyte quality and quantity diminish as result of the 
cancer treatment. 
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